Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) for the Treatment of Newly Diagnosed AL Amyloidosis: Impact of Response on Survival Outcomes

Published:2020-06 Issue:6 Volume:20 Page:394-399
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Diaz-Pallares Carolina,Lee Holly,Luider Joanne,Duggan Peter,Neri Paola,Tay Jason,MacCulloch Sylvia,Bahlis Nizar J.,Jimenez-Zepeda Victor H.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference20 articles.

1. Molecular mechanisms of amyloidosis;Merlini;N Engl J Med,2003

2. Cyclophosphamide, bortezomib and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression free survival;Venner;Blood,2019

3. Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment of naive patients with high risk cardiac AL amyloidosis (Mayo Clinic stage III);Jaccard;Haematologica,2014

4. Bortezomib-containing regimens for the treatment of newly diagnosed and relapsed amyloid light chain amyloidosis: a single-center experience;Jimenez-Zepeda;Clin Lymphoma Myeloma Leuk,2016

5. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone;Kastritis;Haematologica,2007

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Minimal residual disease in systemic light chain amyloidosis: a systematic review and meta-analysis;Journal of Cancer Research and Clinical Oncology;2024-04-15

2. Emerging therapeutic avenues in cardiac amyloidosis;European Journal of Pharmacology;2023-12

3. Cardiac and renal AL amyloidosis controlled by autologous stem cell transplantation for 17 years accompanying late onset atrial fibrillation and complete atrioventricular block;CEN Case Reports;2023-02-16

4. Bad players in AL amyloidosis in the current era of treatment;Expert Review of Hematology;2023-01-02

5. Real-world treatment patterns, costs, and outcomes in patients with AL amyloidosis: analysis of the Optum EHR and commercial claims databases;Amyloid;2022-10-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3